Mylan(MYL)
Mylan N.V. was a global generic and specialty pharmaceuticals company. In November 2020, Mylan merged with Upjohn, Pfizer's off-patent medicine division, to form Viatris. Previously, the company was domiciled in the Netherlands, with principal executive offices in Hatfield, Hertfordshire, UK and a "Global Center" in Canonsburg, Pennsylvania, US.
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
*Currency in USD
Company Revenue
Quarterly
Quarterly
Annual
Annual
Projections
Mock data
Subscribe for the real data
Subscribe for the real data
Revenue by Drug
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name | Drug Name | Approved | Patent Expires | Indication |
|---|---|---|---|---|
| Abacavir | Abacavir | 2012-06-18 | 2027-2029 | |
| Abevmy | Bevacizumab | 2021-04-21 | ||
| Abiraterone | Abiraterone | 2018-10-31 | 2027-2038 | |
| Abiraterone mylan | Abiraterone | 2021-08-20 | 2027-2038 | |
| Acamprosate | Acamprosate | 2014-03-11 | ||
| Accuneb | Albuterol | 2001-04-30 | 2024-2041 | |
| Acebutolol | Acebutolol | 1995-04-24 | ||
| Acetaminophen | Acetaminophen | 2020-08-07 | 2025-2039 | |
| Acetazolamide | Acetazolamide | 2012-05-09 | ||
| Acitretin | Acitretin | 2015-09-10 | ||
| Acyclovir | Acyclovir | 1998-04-13 | 2027-2030 |
1
2
3
4
5
6
...
53
>
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Indication |
|---|---|---|---|---|---|
1
2
3
4
5
6
...
13
>
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use